Novo Nordisk to cut Wegovy, Ozempic and Rybelsus list price to $675 a month in 2027

Novo Nordisk will lower the list price of its three semaglutide medicines to $675 per month, the company announced on February 24, 2026. The new price for Wegovy, Ozempic and Rybelsus takes effect January 1, 2027 ^[2].

List price, also called wholesale acquisition cost, is the sticker price before rebates and discounts — not what most insured patients pay at the counter. Novo Nordisk said the change equals a reduction of about 50% for Wegovy and about 35% for Ozempic from their current list prices ^[2]. The company did not give a percentage for Rybelsus, and none of the announcements stated the current list prices in dollars ^[2].

The new price covers all doses: Wegovy injection 2.4 mg and Wegovy tablets 25 mg, Ozempic injection 0.5 mg, 1 mg and 2 mg, and Rybelsus tablets 7 mg and 14 mg ^[2]. Novo Nordisk said the change will not affect direct-to-patient self-pay prices, including self-pay through NovoCare Pharmacy ^[1][2].

Jamey Millar, executive vice president of US Operations at Novo Nordisk, said private and public payers, as well as patients, "want access and have been calling for lower list prices" ^[2]. The company said more than 100 million people in the United States live with obesity and more than 35 million have type 2 diabetes ^[2].

The benefits consultants Mercer wrote that Novo Nordisk is expected to offset the lower list price by reducing rebates, which would likely mean no meaningful change in net costs after rebates and limited impact on overall employer budgets ^[1]. Mercer also said the change affects what patients see at the counter more than what plans ultimately pay ^[1].

Because a lower list price reduces the value of rebates, Mercer said, employer strategies that cut into rebate value — such as requiring participation in lifestyle management programs, limiting coverage to higher-risk groups, or using BMI-based criteria — may carry smaller tradeoffs ^[1]. The consultants added that employers who do not currently cover weight loss medications may look at covering newer obesity-related indications such as metabolic dysfunction-associated steatohepatitis or cardiovascular risk reduction ^[1].

Why it matters for patients

List price matters most to people whose out-of-pocket costs are tied to it — those in high-deductible health plans or with coinsurance benefit designs, who pay a percentage of the drug's price rather than a flat copay ^[1][2]. For that group, a lower list price generally means a smaller bill at the pharmacy counter ^[1]. Patients who pay a flat copay may not see a change at the counter, and people paying cash through the company's self-pay channel will not see a change from this announcement ^[1][2].

Mercer noted that the new list price is still higher than some direct-to-consumer offerings ^[1]. Whether other manufacturers cut their own list prices in response has not been reported ^[1].

What happens next

January 1, 2027 is also when the Medicare maximum fair price for these drugs is set to take effect, according to Mercer ^[1]. The company said the timing gives employers time to account for the change in their 2027 pharmacy planning ^[1].

Mercer said pharmacies may temporarily reduce inventory ahead of the price change, which could cause short delays for members at the counter ^[1]. The consultants also wrote that a new oral weight loss product is expected to launch as soon as April 2026, and that three additional injectable weight loss products could become available in 2027, including one from a manufacturer new to the market ^[1]. They said the lower list price may pressure newer products to launch at comparable or lower prices ^[1].